Who are the AI in Oncology for Analytical Solutions Market Top Vendors and What are Their Offerings?
What is Meant by AI in Oncology for Analytical Solutions?
The AI in oncology for analytical solutions market is driven by growing incidences of cancer, increasing demand for personalized treatment, and scalable diagnostic tools. The AI in oncology for analytical solutions refers to the use of artificial intelligence technologies for the analysis of cancer-related data and to support cancer diagnostics, clinical, and research decisions. These solutions are being used for cancer detection, classification of cancer types, prediction of cancer recurrences, treatment planning, forecasting treatment response, etc.
Company Profile
| Company | Headquarters | AI Capabilities | Oncology Contribution | Focus Area | AI Analytical Solutions for Oncology |
| Tempus AI | Chicago, U.S. | Integrates clinical, genomic & imaging data with AI for diagnosis & therapy matching | Enables personalized treatment plans & trial stratification at scale | Genomics-AI integration | Tempus Next and Tempus One |
| ConcertAI | Cambridge, U.S. | AI-driven RWD insights, clinical trial acceleration, CARAai & TeraRecon solutions | Speeds trial design, enriches evidence, improves imaging workflows | Trials & outcomes | CARAai |
| PathAI | Boston, U.S. | Enhances tissue slide analysis with deep learning | Boosts diagnostic accuracy & biomarker discovery | Pathology analytics | AISight Dx |
| Paige AI | New York, U.S. | Whole-slide image interpretation for cancer detection | Early detection & expanded oncology indications | AI in pathology | Paige Prostate Suite |
| Siemens Healthineers | Erlangen, Germany | AI-embedded diagnostics & workflow tools | Improves imaging precision in tumour detection | Imaging tech | AI-Pathway Companion |
| GE HealthCare | Chicago, U.S. | AI suites for diagnostic radiology & cancer care | Enhances screening, workflow & clinical throughput | Imaging integration | Precision DL |
| Lunit | Seoul, South Korea | Biomarker analysis & digital pathology tools | Supports drug development & biomarker discovery | Biomarker AI | Lunit INSIGHT and Lunit SCOPE |
| Ibex Medical Analytics | Tel Aviv, Israel | Expanded AI modules for tumor subtyping & biomarkers | Enriches early detection & therapeutic insights | Pathology AI | Galen Platform |
| Artera | Menlo Park, U.S. | AI tests to guide therapy decisions (e.g., prostate) | Personalizes treatment plans with prognostic data | Predictive oncology | ArteraAI Prostate Test |
| Qure.ai | Mumbai, India | AI tools for lung cancer detection & lesion tracking | Aids automated tumor measurement & clinical decisions | Imaging & measurement | qCT-Lung |
Market Growth
The global AI in oncology for analytical solutions market size was estimated at USD 1.62 billion in 2025 and is predicted to increase from USD 2.19 billion in 2026 to approximately USD 33.87 billion by 2035, expanding at a CAGR of 35.54% from 2026 to 2035.
What are the Major Recent Developments in the Market?
- In February 2026, India’s first smart mobile cancer screening bus, consisting of AI-integrated imaging solutions, such as AI-enabled mobile digital mammography and digital radiography systems to offer high-quality screening services in non-traditional care settings, was launched by BPL Medical Technologies.
- In October 2025, an Artificial Intelligence (AI)-based tool, titled RadGLO, for the diagnosis and analysis of brain tumours non-invasively, was launched by the Indian Institute of Technology (IIT) Hyderabad, where it helps in personalised and non-invasive treatment planning, by extracting the vital genetic-level insights directly from standard MRI scans.
Simplify analysis. Strengthen strategy. Own the AI in Oncology for Analytical Solutions Market view - Access the Dashboard
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking
